{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-006760","form_type":"8-K","ticker":"PAHC","cik":"0001069899","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.409627+00:00","generated_at":"2026-05-22T06:50:55.914736+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Phibro Animal Health Q3 net sales up 32% to $347.8M; Adj EBITDA +85%; raises FY2025 guidance","bullets":["Q3 net sales $347.8M (+32% YoY); net income $20.9M (+$12.5M); diluted EPS $0.51 (+$0.30).","Adjusted EBITDA $54.9M (+85% YoY); adjusted diluted EPS $0.63 (+$0.32).","Animal Health segment sales +42% driven by Zoetis MFA acquisition; legacy Animal Health flat.","Updated FY2025 guidance: net sales $1.26B-$1.29B, Adj EBITDA $177M-$183M (62% growth at midpoint).","Gross leverage ratio 3.0x; free cash flow $49.1M for trailing twelve months."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-006760","json":"https://secwatch.observer/filing/0001558370-25-006760.json","markdown":"https://secwatch.observer/filing/0001558370-25-006760.md","text":"https://secwatch.observer/filing/0001558370-25-006760.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069899/000155837025006760/0001558370-25-006760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069899/000155837025006760/pahc-20250507x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T06:50:55.914736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}